Charles River Laboratories Intl. (CRL) Price Target Raised to $120.00 at JPMorgan Chase & Co.

Charles River Laboratories Intl. (NYSE:CRL) had its price target lifted by research analysts at JPMorgan Chase & Co. from $110.00 to $120.00 in a report issued on Wednesday. The firm presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.’s target price would suggest a potential upside of 8.78% from the company’s current price.

CRL has been the subject of several other reports. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Friday, November 10th. SunTrust Banks raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and increased their price objective for the company from $107.66 to $125.00 in a report on Wednesday. Zacks Investment Research lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Argus initiated coverage on Charles River Laboratories Intl. in a report on Wednesday, December 13th. They set a “buy” rating and a $120.00 price objective for the company. Finally, Bank of America reduced their price objective on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, November 10th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Charles River Laboratories Intl. has an average rating of “Buy” and an average price target of $115.15.

Charles River Laboratories Intl. (NYSE CRL) traded up $2.65 during mid-day trading on Wednesday, hitting $110.31. The stock had a trading volume of 1,243,423 shares, compared to its average volume of 469,156. The company has a market capitalization of $4,830.40, a price-to-earnings ratio of 26.93, a PEG ratio of 1.50 and a beta of 0.74. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. Charles River Laboratories Intl. has a 52 week low of $86.25 and a 52 week high of $119.05.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Tuesday, February 13th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.14. The company had revenue of $478.50 million during the quarter, compared to analyst estimates of $475.02 million. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. Charles River Laboratories Intl.’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.21 earnings per share. equities research analysts anticipate that Charles River Laboratories Intl. will post 5.14 earnings per share for the current year.

In other Charles River Laboratories Intl. news, Director Online Communications Bdirect sold 131,000 shares of the stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $0.29, for a total transaction of $37,990.00. Also, Director C Richard Reese sold 10,227 shares of the stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total value of $1,047,244.80. Following the sale, the director now owns 51,444 shares in the company, valued at approximately $5,267,865.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 195,673 shares of company stock worth $2,644,046. Company insiders own 2.20% of the company’s stock.

Several large investors have recently bought and sold shares of the business. BlackRock Inc. raised its position in shares of Charles River Laboratories Intl. by 0.8% in the fourth quarter. BlackRock Inc. now owns 4,034,318 shares of the medical research company’s stock worth $441,557,000 after buying an additional 31,676 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Charles River Laboratories Intl. by 4.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,398,700 shares of the medical research company’s stock worth $153,088,000 after buying an additional 58,991 shares in the last quarter. State Street Corp raised its position in shares of Charles River Laboratories Intl. by 2.3% in the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock worth $128,288,000 after buying an additional 28,365 shares in the last quarter. Mackenzie Financial Corp raised its position in shares of Charles River Laboratories Intl. by 15.3% in the fourth quarter. Mackenzie Financial Corp now owns 1,071,178 shares of the medical research company’s stock worth $117,240,000 after buying an additional 142,382 shares in the last quarter. Finally, TimesSquare Capital Management LLC raised its position in shares of Charles River Laboratories Intl. by 181.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 915,600 shares of the medical research company’s stock worth $100,212,000 after buying an additional 589,900 shares in the last quarter. Hedge funds and other institutional investors own 97.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Charles River Laboratories Intl. (CRL) Price Target Raised to $120.00 at JPMorgan Chase & Co.” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/charles-river-laboratories-intl-crl-price-target-raised-to-120-00-at-jpmorgan-chase-co.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply